301 related articles for article (PubMed ID: 3104456)
1. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
[TBL] [Abstract][Full Text] [Related]
2. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis.
Stern JJ; Oca MJ; Rubin BY; Anderson SL; Murray HW
J Immunol; 1988 Jun; 140(11):3971-7. PubMed ID: 3131421
[TBL] [Abstract][Full Text] [Related]
3. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response.
Squires KE; Schreiber RD; McElrath MJ; Rubin BY; Anderson SL; Murray HW
J Immunol; 1989 Dec; 143(12):4244-9. PubMed ID: 2512353
[TBL] [Abstract][Full Text] [Related]
4. Role and effect of IL-2 in experimental visceral leishmaniasis.
Murray HW; Miralles GD; Stoeckle MY; McDermott DF
J Immunol; 1993 Jul; 151(2):929-38. PubMed ID: 8335921
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity.
Murray HW; Squires KE; Miralles CD; Stoeckle MY; Granger AM; Granelli-Piperno A; Bogdan C
J Immunol; 1992 Mar; 148(6):1858-63. PubMed ID: 1541824
[TBL] [Abstract][Full Text] [Related]
6. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
[TBL] [Abstract][Full Text] [Related]
7. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
[TBL] [Abstract][Full Text] [Related]
8. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
9. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
10. The importance of TGF-beta in murine visceral leishmaniasis.
Wilson ME; Young BM; Davidson BL; Mente KA; McGowan SE
J Immunol; 1998 Dec; 161(11):6148-55. PubMed ID: 9834100
[TBL] [Abstract][Full Text] [Related]
11. [TH1 response in the experimental infection with Trypanosoma cruzi].
Cardoni RL; Antúnez MI; Abrami AA
Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
[TBL] [Abstract][Full Text] [Related]
12. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
Satoskar AR; Rodig S; Telford SR; Satoskar AA; Ghosh SK; von Lichtenberg F; David JR
Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
Murray HW; Montelibano C; Peterson R; Sypek JP
J Infect Dis; 2000 Nov; 182(5):1497-502. PubMed ID: 11023473
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific Il-4- and IL-10-secreting CD4+ lymphocytes increase in vivo susceptibility to Trypanosoma cruzi infection.
Barbosa de Oliveira LC; Curotto de Lafaille MA; Collet de Araujo Lima GM; de Almeida Abrahamsohn I
Cell Immunol; 1996 May; 170(1):41-53. PubMed ID: 8660798
[TBL] [Abstract][Full Text] [Related]
15. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
16. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
Lehmann J; Enssle KH; Lehmann I; Emmendörfer A; Lohmann-Matthes ML
J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
[TBL] [Abstract][Full Text] [Related]
17. An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice.
Engwerda CR; Smelt SC; Kaye PM
Exp Parasitol; 1996 Nov; 84(2):195-202. PubMed ID: 8932769
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
19. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice.
Sato N; Kuziel WA; Melby PC; Reddick RL; Kostecki V; Zhao W; Maeda N; Ahuja SK; Ahuja SS
J Immunol; 1999 Nov; 163(10):5519-25. PubMed ID: 10553079
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
Strauss-Ayali D; Baneth G; Shor S; Okano F; Jaffe CL
Int J Parasitol; 2005 Jan; 35(1):63-73. PubMed ID: 15619517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
